RE:RE:RE:RE:Management and the future
Yes, the lack of partnering is an issue. M&A not so much since no one is going to shell out $1B+ for a company with no human trial results in a field where rats have been unreliable.
But I've yet to discover any big pharma player touting its cutting edge research into protein misfolding. The CNS field has been dominated by players exploring natural drugs, or their modified variants, which were "serendipitously" discovered to offer some symptomatic benefit to some population. These things have momentum, internal politics determine the pace of change and Promis has yet to post any eye-popping results.